BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17

• 

  Rare diseases

  Consummate chameleon Amylyx nears regulatory run in obesity surgery complication

  After suffering the market withdrawal of its only product, Amylyx is gearing up for a pivotal Phase 3 readout in post-bariatric hypoglycemia. But the company’s driving ethos is still to treat “debilitating, devastating” neurodegenerative diseases, co-CEO Justin Klee told BioSpace.

  June 15, 2026

   · 

  5 min read

   · 

  Heather McKenzie
• 

  IN PARTNERSHIP WITH INTELLIA THERAPEUTICS

  The commercial launch playbook: Team structure, readiness and execution

  Intellia Therapeutics’s Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core.

  June 15, 2026

   · 

  6 min read

   · 

  Jennifer C. Smith-Parker
• 

  Cancer

  Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

  Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.

  June 15, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

  Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.

  June 15, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Sanofi wins type 1 diabetes nod for Tzield after requesting to revoke CNPV

  Sanofi makes no mention of the Commissioner’s National Priority Voucher. Tzield was awarded the ticket in October 2025, but Sanofi requested withdrawal from the program after former CDER head Tracy Beth Høeg reportedly expressed skepticism of the drug.

  June 15, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pancreatic cancer

  Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3

  Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.

  June 15, 2026

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Neumora discards depression asset, lays off staffers after pair of late-stage flops

  Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

  June 15, 2026

   · 

  2 min read

   · 

  Gabrielle Masson
• 

  Psychedelics

  Despite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatment

  DemeRx is launching the first U.S. clinical trial of an ibogaine-derived drug candidate, marking a pivotal moment for a controversial psychedelic long sidelined by safety concerns.

  June 15, 2026

   · 

  10 min read

   · 

  Gabrielle Masson
• 

  Policy

  Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments: Reuters

  Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.

  June 15, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Psychedelics

  How does ibogaine work? Understanding matrix logic to make a safer drug

  Ibogaine’s unconventional “matrix pharmacology” may underlie both its therapeutic promise and unpredictable cardiac risks. Unraveling this mechanism could help drug developers hoping to bring ibogaine analogs to market.

  June 15, 2026

   · 

  3 min read

   · 

  Gabrielle Masson